It is worth emphasizing that, due to the remarkable consistence between existing tumor immunity (e.g. TILs) and anti-PD-1 treatment MOAs we observed among the four models tested, it seems that the pre-existing tumor immunity (baseline) dictates the MOA of a given I/O therapy and its efficacy. The gene discussed is PDCD1; the disease is neoplasm.